Core Viewpoint - The company Xinwei Medical-B (06609.HK) announced changes in its governance structure in response to the new Company Law of the People's Republic of China, which will take effect on July 1, 2024 [1] Group 1: Governance Changes - According to the new Company Law, joint-stock companies can establish an audit committee composed of directors to exercise the powers previously held by the supervisory board, eliminating the need for a supervisory board [1] - On December 12, 2025, the board of directors will propose the cancellation of the supervisory board, with its powers being transferred to the audit committee [1]

认购事项所得款项总额为4500万港元。经扣除公司就认购事项应付的专业费用及其他费用后，认购事项 的全部所得款项净额约为4325万港元(相当于约人民币3926万元)，即每股认购股份净价约为43.25港元。 该等所得款项净额拟分配作医疗器械行业的投资及并购机会，目前预计将于2028年12月31日前悉数动 用。 格隆汇12月12日丨心玮医疗-B(06609.HK)宣布，为进一步提升公司的整体竞争力、为集团经营活动筹集 额外资金及促进集团业务稳定发展，于2025年12月12日，董事会决议建议根据特别授权发行认购股份， 且公司与认购方(公司副总裁、首席财务官、首席运营官兼联席公司秘书张涵)订立认购协议，据此，公 司有条件同意配发及发行，而认购方有条件同意认购合共100万股内资股，认购价为45.00港元，较紧接 认购协议日期前的交易日联交所所报每股H股收市价(即45.50港元)折让约1.10%。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或 因依賴該等內容而引致的任何損失承擔任何責任。 Shanghai HeartCare Medical Technology Corporation Limited 上 海 心 瑋 醫 療 科 技 股 份 有 限 公 司 （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股份代號：6609） 建議取消監事會；及 建議修訂組織章程細則 本公告由上海心瑋醫療科技股份有限公司（「本公司」）根據香港聯合交易所有 限公司（「聯交所」）證券上市規則（「上市規則」）第13.51(1)及第13.51(2)條而刊發。 本公司董事（「董事」）會（「董事會」）宣佈，本公司擬向本公司股東（「股東」）提 案，以取消本公司監事會（「監事會」）及修訂本公司現行組織章程細則（「細則」）。 建議取消監事會 根據於 2024 年 7 月 1 日 起 施 行 的《中 華 人 民 共 和 國 公 司 法》修 正 案（「新《公 司 法》」），股份有限公司可以 ...

Shanghai HeartCare Medical Technology Corporation Limited 上 海 心 瑋 醫 療 科 技 股 份 有 限 公 司 （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股份代號：6609） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或 因依賴該等內容而引致的任何損失承擔任何責任。 (1)建議根據特別授權發行內資股及認購協議； (2)授權董事會處理發行認購股份相關事宜； 及 (3)建議修訂組織章程細則 董事會謹此宣佈，為進一步提升本公司的整體競爭力、為本集團經營活動籌 集額外資金及促進本集團業務穩定發展，於2025年12月12日，董事會決議建 議根據特別授權發行認購股份，且本公司與認購方訂立認購協議，據此，本 公司有條件同意配發及發行，而認購方有條件同意認購合共1,000,000股內資 股，認購價為45.00港元。 – 1 – 根據認購協議、組織章程細則及中國相關法律法規，建議根據特別授權發行 認購股份及認 ...

Core Viewpoint - The demand for neurointerventional medical devices in China is increasing due to the rising incidence of cerebrovascular diseases, with stroke being the leading cause of death among Chinese residents. The market for neurointerventional consumables is projected to grow significantly in the coming years [1][5]. Industry Definition and Classification - Neurointerventional devices are medical consumables required for neurointerventional surgeries, primarily used to diagnose and treat cerebrovascular diseases through minimally invasive techniques [2][3]. Industry Development Status - The global market for neurointerventional consumables is expected to reach $3.292 billion in 2024, with North America holding a 43.04% market share. The Chinese market for these consumables is projected to grow from 3.504 billion yuan in 2024 to 4.879 billion yuan in 2025 [5][6]. Industry Chain - The upstream of the neurointerventional device industry consists of raw material suppliers, while the midstream includes manufacturers like Medtronic and Johnson & Johnson. The downstream consists of medical institutions that utilize these devices [7]. Industry Development History - The neurointerventional device industry in China has evolved through three stages: the embryonic stage (1980-1999), the initiation stage (2000-2010), and the rapid development stage (2011-present) [8]. Competitive Landscape - The market is primarily dominated by multinational companies such as Medtronic and Johnson & Johnson, while domestic companies like Guichuang Tongqiao and Micron Brain Science are gaining ground through competitive pricing and localized channels [9][10]. Key Enterprises - The leading companies in the Chinese neurointerventional market include Medtronic, Stryker, and Johnson & Johnson, with a significant presence of domestic players like Guichuang Tongqiao and Micron Brain Science [10][11]. Technological Breakthroughs - Domestic companies are achieving technological advancements in core products, allowing them to compete more effectively with international standards while benefiting from cost advantages [12]. Application Scenario Expansion - The application of new technologies such as AI-assisted navigation systems and biodegradable materials is expected to enhance the efficiency and scope of neurointerventional procedures, supported by favorable government policies [13].

致：香港交易及結算所有限公司 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 公司名稱: 上海心瑋醫療科技股份有限公司 (於中華人民共和國註冊成立的有限責任公司) 呈交日期: 2025年12月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06609 | 說明 | H股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 31,565,804 | RMB | | 1 | RMB | | 31,565,804 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 31,565,804 | RMB | | 1 | RMB | | 31 ...

Core Insights - The neurovascular intervention medical consumables market in China is rapidly growing, with a projected market size of 132.56 billion yuan in 2024 and an expected increase to 197.22 billion yuan by 2025, indicating a significant growth trajectory in this sector [1][3]. Market Overview - The neurovascular intervention medical consumables market is categorized into three main segments: hemorrhagic intervention consumables (71.36 billion yuan, 53.83%), ischemic intervention consumables (35.04 billion yuan, 26.43%), and access intervention consumables (26.16 billion yuan, 19.73%) for 2024 [1][4]. - By 2025, the market shares are expected to shift slightly, with hemorrhagic intervention consumables projected to reach 109.95 billion yuan (55.75%), ischemic intervention consumables at 48.79 billion yuan (24.74%), and access intervention consumables at 38.48 billion yuan (19.51%) [1][4]. Industry Development - The neurovascular intervention field is recognized as a revolutionary advancement in neuroscience, providing less invasive treatment options compared to traditional open surgeries [3]. - The market has grown from 32.25 billion yuan in 2017 to 132.56 billion yuan in 2024, showcasing a robust annual growth rate [3]. Competitive Landscape - The market has historically been dominated by international giants such as Medtronic and Stryker, which held over 60% of the market share [5]. - Domestic companies like MicroPort NeuroScience, Xinwei Medical, Guichuang Tongqiao, and Peijia Medical have made significant advancements in product development, particularly in thrombectomy stents and embolization coils, enhancing their market competitiveness [5]. Industry Trends - The neurovascular intervention medical consumables industry is experiencing rapid growth driven by increased healthcare investment, rising consumer payment capabilities, and an aging population [7]. - There is a notable trend towards domestic companies achieving breakthroughs in lower-tech areas, with expectations for expansion into more advanced fields such as flow-directed devices and intracranial drug balloons [7].

Core Insights - The endovascular neurointervention for cerebral infarction has experienced explosive growth in China, driven by an aging population and lifestyle changes, leading to a continuous rise in the incidence of cerebral infarction [1][4][12] - The number of endovascular neurointervention procedures is projected to increase significantly, reaching 182,500 in 2024 and 266,600 in 2025 [1][5][4] Industry Definition and Barriers - Cerebral infarction, or acute ischemic stroke (AIS), accounts for approximately 80% of all strokes, primarily affecting individuals aged 45 to 70, with an increasing proportion of younger patients [2][4] - The industry has significant talent and brand barriers, as it requires specialized medical knowledge and substantial funding for product development and market entry [3][4] Current Industry Development - The endovascular neurointervention market has seen a rise from 24,100 procedures in 2017 to 182,500 in 2024, with expectations to reach 266,600 by 2025 [4][5] - The breakdown of procedures in 2024 includes intracranial stent retrieval (84,400 procedures, 46.25%), intracranial thrombectomy (66,500 procedures, 36.44%), and other procedures (31,600 procedures, 17.32%) [5] Industry Chain Structure - The industry chain includes upstream raw materials, production and diagnostic equipment, and professional support services, which influence the overall operation of the midstream device manufacturing and downstream clinical treatment [4][6] Major Companies - Key players in the market include Weikang Medical, Xinyi Medical, and Guichuang Tongqiao, among others, with increasing competition as demand grows [8][9] - Microinvasive Brain Science has established a comprehensive product line for stroke intervention, achieving significant revenue growth from 80 million yuan in 2019 to 402 million yuan in 2024 [9] - Guichuang Tongqiao reported a revenue of 780 million yuan in 2024, a 48.3% increase year-on-year, with a gross profit of 560 million yuan [9][10] Industry Development Trends - The market is expected to grow due to rising economic levels, lifestyle changes, and an aging population, with significant opportunities for domestic device manufacturers [12][13] - The industry is expanding its application range, moving beyond ischemic and hemorrhagic strokes to include complex lesions and combinations with other treatment methods [12][13]

Core Insights - The brain-computer interface (BCI) sector in China is experiencing significant advancements, with the first invasive BCI product entering the special review process by the National Medical Products Administration, marking a critical step towards market approval [1] - The Chinese government is actively promoting the BCI industry through various policies and standards, including the release of the first technical standard for BCI medical devices [1][2] - Clinical practices for BCIs in China are accelerating, with several hospitals initiating clinical applications and trials, positioning China as the second country globally to enter the clinical trial phase for invasive BCIs [3] Industry Developments - The BCI industry is expected to achieve key technological breakthroughs by 2027, establishing an advanced technical, industrial, and standard system, with a goal of nurturing globally influential companies by 2030 [2] - The BCI market is projected to grow significantly, with estimates indicating a market size of approximately $2.62 billion in 2024, reaching $2.94 billion by 2025, and potentially growing to $12.4 billion by 2034 [4] Clinical and Commercial Progress - Major hospitals in China are launching BCI clinical applications, with initiatives such as the first BCI outpatient clinic in Central China and the establishment of specialized clinical wards for BCI technology [3] - The development of BCI technology is seen as a beacon of hope for over 3 billion people suffering from neurological disorders globally [3] Investment Opportunities - Companies like MicroPort NeuroScience and Heartway Medical are actively involved in BCI projects, with MicroPort achieving a significant market share in neuro-interventional medical devices in China [5] - Nanjing Panda Electronics is also engaged in BCI technology development, focusing on multimodal human-computer interaction systems [5]

Core Insights - The brain-computer interface (BCI) sector in China is experiencing significant advancements, with the first invasive wireless BCI system entering the special review process by the National Medical Products Administration, marking a critical step towards market approval [1] - The Chinese government is actively promoting the BCI industry through various policies and standards, including the release of the first technical standard for BCI medical devices, which provides a unified framework for development and regulation [1][2] - By 2027, breakthroughs in key BCI technologies are expected to establish an advanced technical, industrial, and standard system, with the goal of nurturing globally influential companies by 2030 [2] Industry Developments - Clinical practices for invasive BCIs in China are accelerating, with the country becoming the second globally to enter clinical trial phases after the United States [3] - Major hospitals are launching BCI clinical applications, indicating a shift from research-driven to clinically-driven development in the BCI field [3] - The global BCI market is projected to grow from approximately $2.62 billion in 2024 to $2.94 billion in 2025, with expectations to reach $12.4 billion by 2034 [4] Investment Opportunities - Companies like MicroPort NeuroScience and Heartway Medical are actively involved in BCI projects, with MicroPort achieving a significant market share in neuro-interventional medical devices in China [5] - Heartway Medical is set to begin formal clinical trials for its invasive BCI project by the end of 2026, following successful animal testing [5] - Nanjing Panda Electronics is developing a multimodal human-computer interaction system based on BCI technology, indicating ongoing innovation in the sector [5]